×
Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-11-04

Jul 18th, 2018 - Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised of malignant cells, normal stroma, soluble ligands, and tumor-immune contexture; attributes that are unique to each individual patient. This is part...

Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer
http://www.medscape.com/viewarticle/889875

Dec 10th, 2017 - A second PARP inhibitor shows promise in germline mutation metastatic breast cancer and is generally well tolerated compared with standard chemotherapy.

Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
http://www.ascopost.com/issues/february-10-2018/adjuvant-zoledronic-acid-in-early-breast-cancer-is-5-years-better/

Feb 9th, 2018 - THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.

Abstract P4-08-05: Impact of common polymorphisms of CYP19A1 and UGT2B17 gene deletion on early endocrine-responsive postmenopausal breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-05

Jul 22nd, 2018 - Background Polymorphisms of genes involved in estrogen production have been linked to breast cancer risk, prognosis and treatment response. Polymorphisms of the aromatase gene CYP19A1 influence its activity. The UGT2B17 catalyzes glucuronic acid transfer to a variety of substrates, including steroids and drugs like the aromatase inhibitor exemestane. We investigated the impact of two variants o...

Axillary Node Management for Breast Cancer: Is Less More?
https://www.cancertherapyadvisor.com/breast-cancer/breast-cancer-axillary-node-management-treatment/article/713742/

Dec 11th, 2017 - Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings.

Breast Pain Uncommon Symptom of Breast Cancer
http://www.medscape.com/viewarticle/890247

Dec 17th, 2017 - Breast pain is not often a symptom of breast cancer regardless of age, and mostly women need to be reassured that breast pain is both common and benign.

Abstract P1-06-12: Optimizing the use of oncotype Dx in early breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-12

Jul 30th, 2018 - Background: Oncotype Dx (ODX) prognosticates the risk of recurrence and predicts the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast cancer (BC). However, its cost makes it prohibitive for many health care systems. Our objective was to develop a model that uses routine clinical and pathological parameters to identify ODX high risk patients which require adjuvant chemothera...

CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women
http://www.ascopost.com/issues/february-10-2018/cdk-46-inhibitors-may-be-effective-but-more-toxic-in-older-women/

Feb 9th, 2018 - OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or older enrolled in registration trials of these agents.

CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/cdk46-improved-pfs-in-older-women-with-hr-metastatic-breast-cancer-

Dec 7th, 2017 - Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival  benefit similar to that seen in their younger counterparts

Abstract P1-06-07: Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-07

Aug 3rd, 2018 - Purpose: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with substantial risks of disease recurrence. While cytotoxic chemotherapy is commonly administered and reduces recurrence, disease outcomes vary considerably and few prognostic tools are available for risk stratification for TNBC patients. We constructed and validated clinical calculators for invasive-disease ...

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-10

Aug 4th, 2018 - Background: In a cross-stratification analysis performed within the TransATAC cohort, Breast Cancer Index (BCI) and 21-gene Recurrence Score (RS) had a concordance of 58.2% (Sestak et al., Clin Cancer Res, 2016). Restratification by BCI of the low and intermediate RS risk groups led to subgroups with significantly different rates (P < 0.001 and P = 0.003, respectively); in contrast, restratifie...

Abstract P3-08-08: Prognostic associations of plasma hepcidin in early breast cancer (BC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-08

Aug 14th, 2018 - Background: Intra-tumor RNA expression of hepcidin has been linked to adverse metastasis-free survival in women with early BC, but the prognostic implications of this inflammatory marker and iron-regulating peptide are unknown. Methods: Using an ELISA assay, we measured plasma hepcidin in the banked blood of 518 women who were recruited from 1989-1996 for a prospective cohort study regarding di...

Abstract P3-08-13: Serum thymidine kinase activity is an independent prognostic factor for progression-free and overall survival in women with metastatic breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-13

Aug 20th, 2018 - Introduction: Although prognosis and treatment of metastatic breast cancer (MBC) have improved over the last years, there is still an unmet clinical need for more precise prognostic and treatment monitoring tools. Liquid-based markers are preferred since they reflect real-time tumor progression and are not dependent on repeated invasive tissue biopsies. Thymidine kinase 1 (TK1) is an enzyme inv...

Dosing Modifications Shown to Improve Outcomes In Breast Cancer
https://www.targetedonc.com/conference/2017-sabcs/dosing-modifications-shown-to-improve-outcomes-in-breast-cancer

Dec 5th, 2017 - Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.

Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
https://www.mdedge.com/oncologypractice/article/155272/breast-cancer/enzalutamide-plus-exemestane-improves-pfs-hr-breast

Jan 1st, 2018 - Enzalutamide added to exemestane improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer, investigators reported

ERBB2 expression predicts pCR in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155137/breast-cancer/erbb2-expression-predicts-pcr-her2-breast-cancer

Dec 25th, 2017 - Among patients receiving trastuzumab plus lapatinib neoadjuvant therapy for HER2-positive early breast cancer, amplification of ERBB2 was predictive of a pathologic complete response (pCR), according to findings presented at the San Antonio Breast Cancer Symposium.

Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-report...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-01

Aug 23rd, 2018 - Background: SOLE efficacy results presented at ASCO 2017 showed that extended intermittent vs continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women who had received 4-6 years of adjuvant endocrine therapy for hormone-receptor positive (HR+), lymph-node positive breast cancer. Previous studies showed that the burden by symptoms related to endocrine therap...

Exemestane plus enzalutamide extends PFS in some women with breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B99e9af8c-7703-431e-ab0d-71b296bb9b5b%7D/exemestane-plus-enzalutamide-extends-pfs-in-some-women-with-breast-cancer

Dec 7th, 2017 - The addition of enzalutamide to exemestane significantly prolonged PFS and appeared well tolerated among patients with hormone receptor-positive metastatic breast cancer who had not received prior endocrine therapy and who expressed an androgen receptor gene signature, according to results of a placebo-controlled randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Extended Endocrine Therapy in Postmenopausal Women With Breast Cancer: 2 Years as Effective as 5 Years
http://www.ascopost.com/issues/december-25-2017/extended-endocrine-therapy-in-postmenopausal-women-with-breast-cancer-2-years-as-effective-as-5-years/

Dec 24th, 2017 - An additional 5 years of aromatase inhibitor therapy after 5 years of adjuvant endocrine therapy failed to improve disease-free survival compared with an additional 2 years of aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive breast cancer, according to the results of the large Austrian Breast and Colorectal Cancer Study Group (ABCSG)-16 trial presented at the 2...

Abstract P5-18-04: Bridging gaps in breast cancer care: A pilot forum for mental health professionals
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-04

Aug 25th, 2018 - Introduction: Supporting the emotional needs of women diagnosed with breast cancer is a recognized priority for cancer clinicians and a core component of high quality care and survivorship programs. We hypothesized that mental health professionals would benefit from an educational program directed to enhance their practical knowledge of breast cancer. Methods: We designed an innovative educatio...